Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Rating) – Research analysts at SVB Leerink dropped their FY2022 earnings per share estimates for shares of Stoke Therapeutics in a research note issued to investors on Monday, November 14th. SVB Leerink analyst R. Li now forecasts that the company will post earnings of ($2.60) per share for the year, down from their prior estimate of ($2.50). SVB Leerink currently has a “Outperform” rating and a $30.00 target price on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.67) per share. SVB Leerink also issued estimates for Stoke Therapeutics’ Q4 2022 earnings at ($0.65) EPS and FY2022 earnings at ($2.60) EPS.
Other equities research analysts have also issued research reports about the company. Needham & Company LLC lowered their target price on Stoke Therapeutics from $50.00 to $25.00 and set a “buy” rating for the company in a research note on Monday. Cantor Fitzgerald lowered their target price on Stoke Therapeutics from $38.00 to $20.00 in a research note on Tuesday. Finally, Credit Suisse Group lowered their target price on Stoke Therapeutics from $50.00 to $38.00 and set an “outperform” rating for the company in a research note on Tuesday. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Stoke Therapeutics currently has a consensus rating of “Buy” and an average target price of $34.86.
Stoke Therapeutics Trading Down 10.1 %
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of STOK. Ensign Peak Advisors Inc bought a new position in Stoke Therapeutics during the 1st quarter valued at approximately $25,000. Point72 Hong Kong Ltd purchased a new position in shares of Stoke Therapeutics during the 1st quarter worth approximately $27,000. Russell Investments Group Ltd. purchased a new position in shares of Stoke Therapeutics during the 2nd quarter worth approximately $28,000. UBS Group AG purchased a new position in shares of Stoke Therapeutics during the 3rd quarter worth approximately $47,000. Finally, Amalgamated Bank purchased a new position in shares of Stoke Therapeutics during the 1st quarter worth approximately $66,000.
About Stoke Therapeutics
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression.
- Get a free copy of the StockNews.com research report on Stoke Therapeutics (STOK)
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ’s Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.